The involvement of the multi-drug-resistant 1 P-glycoprotein gene (MDR1 P-gp) in the transport of antidepressants across the blood-brain barrier makes it a good candidate for the prediction of antidepressant response and side effects. We investigated the role of the MDR1 P-gp gene in predicting the induction of mania in bipolar patients (BP) treated with proserotonergic drugs. Participants met the DSM-IV criteria for BP or BPII and had at least one depressive episode treated with proserotonergic antidepressants. The first group (n¼26) included patients with at least one DSM-IV manic/hypomanic episode developed during antidepressant treatment; the second group (N¼29) included patients with no antidepressant-induced switches. The common polymorphism of the MDR1 was genotyped for both groups and comparison was made with respect to the presence/absence of induced mania between the two groups. No association between antidepressantinduced mania and the MDR1 alleles or genotypes was found (w 2 ¼1.85, 2 df, P¼0.39; w 2 ¼0.13, 1 df, P¼0.72).
INTRODUCTION
The multi-drug-resistant 1 P-glycoprotein gene (MDR1 P-gp), also called ABCB1, is the active transporter system across the blood-brain barrier (BBB).
1 MDR1 gene knockout mice have shown that amitriptyline and nortriptyline, antidepressants used to treat bipolar depression, are good substrates for MDR1 P-gp. 2 Bipolar disorder has been shown to have a strong genetic component; [3] [4] [5] thus, investigation of the genetic component of response to antidepressant drugs in BP is warranted.
The MDR1 is located on chromosome 7q21 and has at least three common single-nucleotide polymorphisms (SNPs). One is in exon 26, consisting of a silent substitution 3435C4T. The C3435 variant has been reported to generate more gene expression than the T3435. 6 Previous research investigating the involvement of the 3435C4T polymorphism in the pharmacological effects of the MDR1 P-gp has led to conflicting results. Among the several association studies performed with blood drug levels, two studies detected a positive association between the T/T genotype and higher plasma level of the P-gp substrate digoxin, 6, 7 while another study found a lower plasma level of another P-gp substrate, fexofenadine, associated with T/T genotype. 8 However, in a recent report, fexofenadine disposition was not significantly different between the CC and TT groups.
While there is discrepancy in the reports on the relationship between the 3435C4T polymorphism and plasma concentration of P-gp substrate, the data on genotypedependent differences in duodenal absorption and P-gp efflux in peripheral blood cells [9] [10] [11] are much more consistent.
Additionally, one psychiatric pharmacogenetics study reported that the T allele was associated with an increased incidence of nortriptyline-induced postural hypotension, although no significant difference of drug concentration in the plasma was observed. 12 Another polymorphism in exon 21, consisting of an SNP with three alleles (893Ala, 893Ser, 893Thr), appears to be in linkage disequilibrium with 3435C4T. 8 To date, only the study of Roberts et al 12 investigated the role of the MDR1 3435C4T polymorphism in antidepressant treatment. There are no studies that investigated the involvement of the MDR1 polymorphism in the induction of mania during antidepressant treatment. The switch to mania in patients treated with antidepressant medications is not a rare side effect and occurs at different rates across different patients with affective disorders. [13] [14] [15] [16] Angst 17 reported that the adverse drug reaction of antidepressant-induced mania was closely linked to BP and schizoaffective disorder, and also found that the switch frequency during antidepressant treatment was eight-fold higher in these disorders than that in patients with unipolar depression. To date, there are no reliable clinical predictors of antidepressant-induced mania. As a result, using a pharmacogenetics approach, we investigated 3435C4T in MDR1 as a predictor of antidepressant induced mania.
MATERIALS AND METHODS
We genotyped 55 subjects with BPI and BPII, who were recruited from Toronto and central Canada. Based on the detailed clinical assessment that we published previously, 18 the first group consisted of 26 subjects with a positive history for antidepressant-induced mania (IM þ group) and the second consisted of 29 subjects without the history of antidepressant-induced mania (IMÀ group). The two groups were matched for age, gender, ethnicity, and clinical features.
Genomic DNA was isolated from whole blood samples using a nonenzymatic method 19 and genotyping for 3435C4T was performed with a modified protocol from Tang A volume of 25 ml of the PCR product was digested with 5 U of the restriction enzyme DpnII, specific for the sequence GATC; this mixture of 30 ml was incubated at 371C over night. The alleles were detected after separation by electrophoresis on a 2.5% agarose gel in TBE at 100 V for 1 h, and stained with ethidium bromide for UV visualization, and the lengths were estimated by standard markers. Allele 1 (T) is not cut with the restriction enzyme and is seen as a 249 bp band. Allele 2 (C) is cut into two bands of 162 and 87 bp. The genotype data were analyzed using w 2 test.
RESULTS
The main demographic (including ethnic background) and clinical variables for both patient groups are described in our previous publication. 18 In the IM þ group, the ongoing antidepressant treatments during the development of manic or hypomanic episodes included fluoxetine hydrochloride (n¼8), fluvoxamine (n¼6), a combination of fluoxetine and fluvoxamine (n¼3), paroxetine (n¼2), nefazodone hydrochloride (n¼2), moclobemide (n¼2), venlafaxine hydrochloride (n¼1), imipramine hydrochloride (n¼2), and sertraline hydrochloride (n¼1). Genotype counts for the 3435C4T polymorphisms in the IM þ sample were TT¼6, TC¼15, and CC¼8, and in the IMÀ group were TT¼4, TC¼18, and CC¼4. The entire sample was in HardyWeinberg equilibrium (w 2 ¼2.235, 1 df, P¼0.13). Results of the association analysis performed with the alleles and genotypes of the 3435C4T polymorphism did not show any significant difference between the patient groups (genotypes: w 2 ¼1.85, 2 df, P¼0.39; alleles: w 2 ¼0.13, 1 df, P¼0.72) ( Table 1) .
DISCUSSION
The main finding from this study appears to exclude a direct involvement of the 3435C4T polymorphism of the MDR1 gene in conferring a higher risk for the development of antidepressant-induced mania in patients with BP. The effect of this polymorphism remains controversial, considering that, in two recent reports, one found the TT genotype to be associated with higher plasma levels of digoxin 6 and the other with lower plasma levels of fexofenadine. 8 The fact that different compounds were used likely contributed to the discordant results. In addition, the involvement of The critical role of MDR1-related proteins (eg MRP), which can influence the bioavailability and CNS concentrations, as well as determining the timing and the extent of the antidepressant response to medication, should be investigated with respect to the 3435C4T variants.
Our negative results could be due to several limitations of the study. Regarding the phenotype of antidepressantinduced mania, spontaneous episodes of mania could be a phenocopy of antidepressant-induced mania creating a bias in the pharmacogenetics study. The occurrence of a depressive episode may naturally anticipate mania and, at the same time, may require antidepressant treatment, leading to an incorrect connection between the two events. 21 In addition, our patients were medicated with a variety of different drugs, and the P-gp has affinity for many substrates, making both confounding factors. Furthermore, a recent in vitro study does not support 22 the involvement of MDR1 in antidepressant transport; however, in an 'in vivo' situation, the MDR1 affinity for the same drugs is very different 2 and for most of the antidepressants used in our study the affinity has not been tested. These difficulties to transfer results from in vitro studies to the in vivo situation are confirmed by two recent reports that found higher concentrations of paroxetine, venlafaxine, doxepin, trimipramine, and citalopram in p-gp knockout mice. 23, 24 On the other hand, the strength of our sample is the compatibility of our two groups: that we did not find statistically significant differences in any of the principal clinical features between IM þ and IMÀ patients. Useful future studies will include larger sample sizes, and examination of broader phenotypes including clinical response to antidepressants.
